The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.

The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.
复制标题

DOI:
10.1007/s10911-018-9416-0
复制
发表时间:
2018-12
影响因子:
2.5
通讯作者:
Edwards DP
Edwards DP
中科院分区:
医学4区
文献类型:
--
作者:
Villanueva H;Grimm S;Dhamne S;Rajapakshe K;Visbal A;Davis CM;Ehli EA;Hartig SM;Coarfa C;Edwards DP

文献摘要

参考文献

相似文献

导管原位癌(DCIS)是大多数类型的浸润性乳腺癌(IBC)的非专性前兆。虽然估计只有三分之一未经治疗的DCIS患者会进展为IBC,但治疗的标准护理是手术和放射。这种治疗方法与缺乏可靠的生物标志物组合来预测DCIS进展相结合是一个主要的临床问题。DCIS与IBC具有相同的分子亚型,包括雌激素受体(ER)和孕激素受体(PR)阳性管腔亚型,其涵盖了大多数(60-70%)DCIS。与ER和PR在腔IBC中的既定作用相比,人们对雌激素(E2)和孕激素(P4)及其相关受体在DCIS发生和发展中的作用和作用机制知之甚少。这是一个未充分探索的研究领域,部分原因是缺乏合适的ER+/PR + DCIS实验模型。这篇综述总结了类固醇激素作为乳腺癌危险因素以及ER和PR作为DCIS生物标志物的临床和观察性研究信息。最后,我们讨论了ER+/PR+ DCIS的新兴实验模型。
Ductal carcinoma in situ (DCIS) is a non-obligate precursor to most types of invasive breast cancer (IBC). Although it is estimated only one third of untreated patients with DCIS will progress to IBC, standard of care for treatment is surgery and radiation. This therapeutic approach combined with a lack of reliable biomarker panels to predict DCIS progression is a major clinical problem. DCIS shares the same molecular subtypes as IBC including estrogen receptor (ER) and progesterone receptor (PR) positive luminal subtypes, which encompass the majority (60–70%) of DCIS. Compared to the established roles of ER and PR in luminal IBC, much less is known about the roles and mechanism of action of estrogen (E2) and progesterone (P4) and their cognate receptors in the development and progression of DCIS. This is an underexplored area of research due in part to a paucity of suitable experimental models of ER+/PR + DCIS. This review summarizes information from clinical and observational studies on steroid hormones as breast cancer risk factors and ER and PR as biomarkers in DCIS. Lastly, we discuss emerging experimental models of ER+/PR+ DCIS.
DOI: 10.1016/j.prp.2017.02.014
发表时间: 2017-01-01
影响因子: 2.8
作者:
Alvarado, Antonieta;Lopes, Ana C.;Colaco, Bruno
通讯作者: Colaco, Bruno
DOI: 10.1038/onc.2017.252
发表时间: 2017-11-16
期刊: ONCOGENE
影响因子: 8
作者:
Ando, S.;Malivindi, R.;Metzger, D.
通讯作者: Metzger, D.
DOI: 10.1186/bcr2358
发表时间: 2009
期刊: Breast cancer research : BCR
影响因子: --
作者:
Behbod F;Kittrell FS;LaMarca H;Edwards D;Kerbawy S;Heestand JC;Young E;Mukhopadhyay P;Yeh HW;Allred DC;Hu M;Polyak K;Rosen JM;Medina D
通讯作者: Medina D
DOI: 10.1001/jama.289.24.3243
发表时间: 2003-06-25
影响因子: 120.7
作者:
Chlebowski, RT;Hendrix, SL;McTiernan, A
通讯作者: McTiernan, A
DOI: 10.1128/mcb.23.6.1994-2008.2003
发表时间: 2003-03-01
影响因子: 5.3
作者:
Ballaré, C;Uhrig, M;Beato, M
通讯作者: Beato, M